MET amplification in NSCLC: Correlation with EGFR mutations and gene amplification

作者
Alexandra Voutsina,Ar. Kalykaki,Anastasios V. Koutsopoulos,Maria Trypaki,E. Stathopoulos,Dimitriοs Mavroudis,Vasilis Georgoulias
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:68: 2169-2169
摘要

2169 Background: MET amplification in NSCLC was correlated with acquired resistance to EGFR TKIs, gefitinib and erlotinib. The aim of this study was to investigate whether MET is amplified in NSCLC prior to TKIs therapy and examine the association of MET amplification with EGFR copy number, mutation status and responsiveness to TKIs.
 Methods: Amplification levels of MET and EGFR genes were determined in FFPE tumor DNA of known EGFR and K-RAS mutation status from 69 patients with advanced NSCLC treated with gefitinib. Quantitative real-time PCR was performed to analyse MET (7q31.2) and EGFR (7p12) gene copy numbers relative to a reference, the TOP3A (17p12-p11.2) gene. Relative copy numbers of the EGFR and MET genes were expressed as the ratio of PCR signals obtained for EGFR or MET and TOP3A . The cutoff for normal copy numbers was established as the 95% confidence upper limit (mean + 1.96 standard deviations) of EGFR/TOP3A and MET/TOP3A determined in DNA of normal matched tissue from 14 patients respectively. Results: Seven (10%) of the 69 primary tumors exhibited increased MET copy number. None of these tumors had an EGFR mutation whereas 3 of them had K-RAS mutation. No significant association was found between MET copy number and TKI-related disease control rate or survival. Among the 7 patients showing MET amplification 2 (28.5%) with EGFR wild type mutation status exhibited progressive disease. EGFR amplification was detected in 5 (7.2%) patients and among them one (20%) showed MET amplification as well. Response rate was not associated with the EGFR amplification. One patient with a Del19 EGFR mutation reached partial response and another one with wild type mutation status achieved stable disease. The patient showing EGFR and MET amplification had not EGFR and K-RAS mutations and exhibited progressive disease. Conclusions : Met amplification is not a common event in NSCLC prior to EGFR TKIs therapy. However the predictive value of chromosome 7 polysomy should be considered with caution.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Samuel发布了新的文献求助10
刚刚
simple完成签到,获得积分10
刚刚
bontayu完成签到,获得积分10
刚刚
刚刚
车车发布了新的文献求助20
刚刚
1秒前
冲冲冲完成签到,获得积分10
1秒前
碎碎发布了新的文献求助10
1秒前
汽水棒冰完成签到,获得积分10
1秒前
orixero的应助被金阿林在科研采纳,获得10
1秒前
1秒前
隐形曼青的应助被qq采纳,获得10
2秒前
米大王发布了新的文献求助10
2秒前
Jasper的应助被Wacky采纳,获得10
2秒前
白开水发布了新的文献求助10
3秒前
高强发布了新的文献求助10
3秒前
3秒前
可爱的函函的应助被张宇采纳,获得10
3秒前
学习的时候不困完成签到,获得积分20
3秒前
麦mai完成签到,获得积分10
3秒前
xudaniel发布了新的文献求助10
3秒前
3秒前
BGW发布了新的文献求助10
3秒前
3秒前
123发布了新的文献求助10
3秒前
4秒前
无极微光的应助被青橙采纳,获得20
4秒前
我是老大的应助被lvchinyang采纳,获得10
4秒前
Yultuz友发布了新的文献求助10
5秒前
小蘑菇的应助被无奈的亦玉采纳,获得10
5秒前
pagoda完成签到,获得积分10
5秒前
JOFM完成签到 ,获得积分10
5秒前
守夜人完成签到,获得积分10
5秒前
5秒前
2293889发布了新的文献求助10
5秒前
老迟到的夏旋完成签到,获得积分10
6秒前
7秒前
7秒前
方源的应助被神经蛙采纳,获得10
7秒前
coco完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160268
求助须知:如何正确求助?哪些是违规求助? 9555328
关于积分的说明 21727231
捐赠科研通 7750062
什么是DOI,文献DOI怎么找? 3427353
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471707